#PPCB

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study Propanc Biopharma (Nasdaq: PPCB) executed a service agreement with FyoniBio to develop and validate an LC-MS pharmacokinetics (PK) assay for its lead asset PRP (trypsinogen and chymotrypsinogen plus activated enzymes) to support a Phase 1b First‑In‑Human study in advanced solid tumor patients. The assay aims for ≤0.1µg/mL sensitivity to quantify four serum analytes. Propanc cites assay validation, GMP manufacture of PRP, and a clinical trial application as three key preparatory activities, and plans to commence the FIH study in the fourth calendar quarter of 2026.

4 days ago

#PPCB Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models Propanc Biopharma (Nasdaq: PPCB) highlights preclinical and near‑term clinical plans for lead asset PRP, an investigational proenzyme therapy targeting metastatic solid tumors. Key points: >85% tumor growth inhibition in pancreatic models, FDA Orphan Drug status for pancreatic cancer, a $100M funding facility, new patents, and a planned Phase 1b first‑in‑human trial in 2026 for 30–40 advanced solid tumor patients.The company positions PRP as a multi‑targeted approach that may sensitize tumors, reduce fibrosis and resistance markers, and potentially lower toxicity versus standard therapies.

1 week ago

#PPCB Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

PenkeTrading

@penkeinvesting.bsky.social

2 weeks ago

Fundamental analysis of $PPCB (Propanc Biopharma, Inc.) based on financial data and reported results.

#PPCB

0 0 0 0

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia Propanc Biopharma (NASDAQ:PPCB) filed a new provisional patent application with IP Australia on January 20, 2026 for methods to produce fully synthetic recombinant trypsinogen and chymotrypsinogen (Rec-PRP).The filing describes an optimized yeast-based expression system to manufacture a world-first fully synthetic version of PRP intended as a long-term therapy to treat and prevent metastatic cancer from solid tumors. Management says Rec-PRP could enable long shelf life without refrigeration, scalable lot-consistent supply without animal sourcing, and improved global distribution. The release cites a projected global metastatic cancer market of $111 billion by 2027 and frames the provisional as the third filing in two months to expand the company IP portfolio ahead of national phase filings worldwide.

1 month ago

#PPCB Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer Propanc Biopharma (Nasdaq: PPCB) described preclinical and market context for its pancreatic proenzyme candidate PRP and outlined next steps toward human studies in 2026. Key facts: PRP is a 1:6 mixture of trypsinogen and chymotrypsinogen; preclinical models showed tumor growth inhibition >85% at some doses and reduced EMT, angiogenesis, and fibrosis; FDA granted Orphan Drug Designation (2017). The company is pre-revenue, raised ~$4M in a recent IPO, and cited a potential $100M private placement facility to fund development. Phase I/II trials are planned for 2026.

1 month ago

#PPCB Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Propanc Biopharma Provides Shareholder Update Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases,

2 months ago

#PPCB Propanc Biopharma Provides Shareholder Update

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent

2 months ago

#PPCB Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis Propanc Biopharma (Nasdaq: PPCB) has requested a foreign filing license from Spain for two provisional patents covering methods to treat resistant cancer and fibrosis. The provisional patents will be filed with IP Australia under Propanc Pty Ltd and are expected to be pursued in key global jurisdictions.The fibrosis provisional is described as a world-first expansion of PRP proenzyme therapy beyond cancer. Propanc says its planned Phase 1b First‑In‑Human study in 2026 will define PRP dosing ahead of Phase 2 proof‑of‑concept studies.

3 months ago

#PPCB Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Upendra Sharma

@upendrasharma.bsky.social

3 months ago

What Are the Key Steps to Obtain PPCB NOC for Business Setup in Punjab?

What Are the Key Steps to Obtain PPCB NOC for Business Setup in Punjab?
enterclimate.com/ppcb-punjab-...
To obtain PPCB NOC industries must classify their category apply online with required documents and ensure proper waste management plan. #PPCB #PunjabBusiness #PollutionNOC #CTO #Enterclimate

0 0 0 0

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported financial results

3 months ago

#PPCB Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent

4 months ago

#PPCB Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) Propanc Biopharma (NASDAQ: PPCB) announced a strategic initiative on Nov 4, 2025 to pursue acquisitions of Digital Asset Treasury (DAT) companies trading below Market Cap to Net Asset Value (MNAV). Management said acquiring undervalued DATs could strengthen Propanc's balance sheet, diversify assets, and create long-term shareholder value while the company continues its oncology development work.The release cites public data showing Bitcoin treasury companies hold approximately $76.9 billion and Ethereum-based DATs hold about $17.6 billion in digital assets. Propanc's board is evaluating targets and building due diligence frameworks and will update shareholders as qualified targets are identified.

4 months ago

#PPCB Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing

4 months ago

#PPCB Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing treatments for recurring and metastatic cancer, announced its fiscal year-end update following the filing of its annual

5 months ago

#PPCB Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

www.stocktitan.net/news/PPCB/propanc-report...

0 0 0 0

$100M Ethereum Investment: Cancer Drug Developer Propanc Makes Bold Move into Crypto for Growth Strategy Nasdaq-listed biotech Propanc Biopharma announces plans to purchase $100M in Ethereum over 12 months. Strategy aims to diversify assets while funding cancer drug development and IP acquisitions.

6 months ago

#PPCB Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

$18.1B Market Potential: Propanc's Novel Cancer Drug PRP Heads to Human Trials After Successful Nasdaq IPO Biotech firm Propanc raises $4M in Nasdaq IPO to advance PRP cancer treatment into Phase 1B trials. Drug targets $18.1B market for pancreatic/ovarian cancers. First human trials set for 2026.

6 months ago

#PPCB Propanc Biopharma Provides Shareholder Update

www.stocktitan.net/news/PPCB/propanc-biopha...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Most Searched, Monday August 18, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Aug 18th - #BSGM #DAWN #SNGX #OPEN #WULF #WRD #SBET #MGNX #LUNR #HIVE #SHCO #ONDS #ARRY #CIFR #DNN #GDRX #VTAK #FFAI #PPCB - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

6 months ago

News; ( OTC: #PPCB ) Healthcare Innovators: Catheter Precision Expands in UK, LIXTE Gains Momentum, BioXcel Nears At-Home Approval Milestone

0 0 0 0

PROMISING NEW CANCER TREATMENT | Greenplanetmicrocaps

6 months ago

News; ( OTC: #PPCB ) The Next Wave of Cancer Innovation: How Breakthrough Therapies Are Redefining Treatment Paradigms

0 0 0 0

Grumpy10

@grumpy10.bsky.social

1 year ago

#PPCB Propanc Biopharma New Way to Treat Cancer
richardacavalli.wixsite.com/greenplanetm...

0 0 0 0

1 year ago

Breaking News: ( OTC: #PPCB ) Propanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North America

#StockMarket #News

1 0 0 0